Javascript must be enabled to continue!
B-336 Comparison of the LZI Fentanyl Enzyme Immunoassay With ARKII and SEFRIA Fentanyl Assays on Beckman AU Analyzer
View through CrossRef
Abstract
Background
Fentanyl is a fast-acting synthetic opioid that can be prescribed for severe pain or found in illicit drugs. Routine clinical screening of fentanyl use is often performed on automated immunoassay analyzers, by measuring fentanyl and/or its primary metabolite, norfentanyl, in urine. Limited data has been published on performance of the relatively new LZI fentanyl enzyme immunoassay, which detects both fentanyl and norfentanyl but calibrated against norfentanyl. In this study, we evaluated the performance of LZI fentanyl assay on Beckman AU analyzer, in comparison to ARKII and SEFRIA assays calibrated against fentanyl.
Methods
The LZI and ARKII fentanyl assays were implemented on Beckman AU 5800 analyzer according to manufacturer’s instructions in our clinical laboratory. The LZI assay uses a cutoff value of 5 ng/mL for norfentanyl, while the ARKII assay uses a cutoff value of 1 ng/mL for fentanyl. The SEFRIA assay was performed on Beckman AU analyzer in a reference laboratory, with a cutoff value of 2 ng/mL for fentanyl. A qualitative comparison study was performed on a total of 42 deidentified urine samples, which were consecutively collected from clinical fentanyl screening test orders. Fentanyl screening results from the LZI and SEFRIA assays were available for all 42 samples, with ARKII results available for 28 out of the 42 samples. LC-MS confirmation test (cutoff value of 1 ng/mL for either fentanyl or norfentanyl) was also performed in a reference laboratory for samples with discrepant LZI results compared to either SEFRIA or ARKII results.
Results
A within day precision of <10% (4.8%–9.7%) and between day precision of <15% (7.0%–13.9%) were observed for the LZI fentanyl assay on Beckman AU analyzers, using calibrator or quality control samples at cutoff level, 25% lower and 25% higher than cutoff level. LZI and ARKII results agreed on 27 out of 28 samples (10 positive and 17 negative). Only one sample tested positive by ARKII but negative by LZI assay, which was also negative by SEFRIA and LC-MS. When compared to SEFRIA assay, results from LZI assay agreed on 35 out of 42 samples (10 positive and 25 negative). The seven discrepant results (negative on SEFRIA but positive on LZI) were all confirmed positive by LC-MS. The false negative results observed on SEFRIA were likely due to a cutoff value of 2 ng/mL instead of 1 ng/mL. There was one sample tested positive by LC-MS only (<1.0 ng/mL for fentanyl and 3.3 ng/mL for norfentanyl), with inconclusive LZI results but counted as negative (positive on one instrument and negative on another). Overall, there was no false positive result reported by LZI assay in this study and 17 out of 18 positive samples were correctly identified, with a calculated sensitivity of 94%, specificity 100%, positive predictive value 100% and negative predictive value 96%.
Conclusion
The Beckman AU LZI fentanyl assay with a cutoff value of 5 ng/mL calibrated against norfentanyl has shown comparable performance as existing fentanyl assays and can be implemented for routine clinical screening of fentanyl.
Title: B-336 Comparison of the LZI Fentanyl Enzyme Immunoassay With ARKII and SEFRIA Fentanyl Assays on Beckman AU Analyzer
Description:
Abstract
Background
Fentanyl is a fast-acting synthetic opioid that can be prescribed for severe pain or found in illicit drugs.
Routine clinical screening of fentanyl use is often performed on automated immunoassay analyzers, by measuring fentanyl and/or its primary metabolite, norfentanyl, in urine.
Limited data has been published on performance of the relatively new LZI fentanyl enzyme immunoassay, which detects both fentanyl and norfentanyl but calibrated against norfentanyl.
In this study, we evaluated the performance of LZI fentanyl assay on Beckman AU analyzer, in comparison to ARKII and SEFRIA assays calibrated against fentanyl.
Methods
The LZI and ARKII fentanyl assays were implemented on Beckman AU 5800 analyzer according to manufacturer’s instructions in our clinical laboratory.
The LZI assay uses a cutoff value of 5 ng/mL for norfentanyl, while the ARKII assay uses a cutoff value of 1 ng/mL for fentanyl.
The SEFRIA assay was performed on Beckman AU analyzer in a reference laboratory, with a cutoff value of 2 ng/mL for fentanyl.
A qualitative comparison study was performed on a total of 42 deidentified urine samples, which were consecutively collected from clinical fentanyl screening test orders.
Fentanyl screening results from the LZI and SEFRIA assays were available for all 42 samples, with ARKII results available for 28 out of the 42 samples.
LC-MS confirmation test (cutoff value of 1 ng/mL for either fentanyl or norfentanyl) was also performed in a reference laboratory for samples with discrepant LZI results compared to either SEFRIA or ARKII results.
Results
A within day precision of <10% (4.
8%–9.
7%) and between day precision of <15% (7.
0%–13.
9%) were observed for the LZI fentanyl assay on Beckman AU analyzers, using calibrator or quality control samples at cutoff level, 25% lower and 25% higher than cutoff level.
LZI and ARKII results agreed on 27 out of 28 samples (10 positive and 17 negative).
Only one sample tested positive by ARKII but negative by LZI assay, which was also negative by SEFRIA and LC-MS.
When compared to SEFRIA assay, results from LZI assay agreed on 35 out of 42 samples (10 positive and 25 negative).
The seven discrepant results (negative on SEFRIA but positive on LZI) were all confirmed positive by LC-MS.
The false negative results observed on SEFRIA were likely due to a cutoff value of 2 ng/mL instead of 1 ng/mL.
There was one sample tested positive by LC-MS only (<1.
0 ng/mL for fentanyl and 3.
3 ng/mL for norfentanyl), with inconclusive LZI results but counted as negative (positive on one instrument and negative on another).
Overall, there was no false positive result reported by LZI assay in this study and 17 out of 18 positive samples were correctly identified, with a calculated sensitivity of 94%, specificity 100%, positive predictive value 100% and negative predictive value 96%.
Conclusion
The Beckman AU LZI fentanyl assay with a cutoff value of 5 ng/mL calibrated against norfentanyl has shown comparable performance as existing fentanyl assays and can be implemented for routine clinical screening of fentanyl.
Related Results
Comparison of the DRI II and LZI I fentanyl immunoassays for in vitro clinical diagnostic use
Comparison of the DRI II and LZI I fentanyl immunoassays for in vitro clinical diagnostic use
Abstract
Introduction
Fentanyl, a highly potent synthetic opioid, has contributed to a rapid rise in opioid-related overd...
Effect of Labor Epidural Analgesia with and without Fentanyl on Infant Breast-feeding
Effect of Labor Epidural Analgesia with and without Fentanyl on Infant Breast-feeding
Background
The influence of labor epidural fentanyl on the neonate is controversial. The purpose of this study was to determine whether epidural fentanyl has an impact ...
Structural characterization of the RH1-LZI tandem of JIP3/4 highlights RH1 domains as a cytoskeletal motor-binding motif
Structural characterization of the RH1-LZI tandem of JIP3/4 highlights RH1 domains as a cytoskeletal motor-binding motif
AbstractJIP3 and JIP4 (JNK-interacting proteins 3 and 4) are adaptors for cargo recruitment by dynein/dynactin and kinesin1 motors. Both are dimers that are stabilised by two secti...
Neuroinflammation and Neurometabolomic Profiling in Fentanyl Overdose Mouse Model Treated with Novel β-Lactam, MC-100093, and Ceftriaxone
Neuroinflammation and Neurometabolomic Profiling in Fentanyl Overdose Mouse Model Treated with Novel β-Lactam, MC-100093, and Ceftriaxone
Opioid-related deaths are attributed to overdoses, and fentanyl overdose has been on the rise in many parts of the world, including the USA. Glutamate transporter 1 (GLT-1) has bee...
Mesolimbic and mesocortical pathways differentially support fentanyl-context associations
Mesolimbic and mesocortical pathways differentially support fentanyl-context associations
Abstract
Rationale
Synthetic opioids like fentanyl are contributing to unprecedented overdose rates, yet the neural circuitry u...
520. Development of Cefepime-taniborbactam MIC Antimicrobial Susceptibility Test (AST) for Enterobacterales and Pseudomonas aeruginosa on MicroScan Dried Gram-negative MIC Panels
520. Development of Cefepime-taniborbactam MIC Antimicrobial Susceptibility Test (AST) for Enterobacterales and Pseudomonas aeruginosa on MicroScan Dried Gram-negative MIC Panels
Abstract
Background
Automated AST devices are critical to inform appropriate care of patients with bacterial infections. Cefepim...
Opioid antagonism in fentanyl antinociception experimental
Opioid antagonism in fentanyl antinociception experimental
Among the most commonly used drugs to reduce pain and inflammation are nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Opioids are a wide group of drugs including fentan...
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
We longitudinally studied 51 patients from two hemodialysis centers to determine the prevalence of hepatitis C virus infection in hemodialysis patients. Serum samples were tested f...

